Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Journal1
- Article Type
- Clinical Trial1
- Clinical Study1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Eur J Cardiol1
Search Results
Sort by
- ArticleFrithz G, Danielson M, Henningsen N, Malmborg RO, Nordström-Ohrberg G, Schröder G.Eur J Cardiol. 1978 Apr-May;7(2-3):131-6.The antihypertensive effect of beta-adrenoceptor blocking drugs has been documented in a number of papers [10--13] and over the last 10 yr beta-receptor blockade has become a more and more frequent primary therapy for hypertension. During this time, a number of different beta-blockers with various degrees of selectivity, potency and intrinsic sympathomimetic effect have come into use. There have also been attempts to reduce the number of daily doses in beta-adrenoceptor blocking therapy while maintaining the antihypertensive effect [5]. Pindolol (Viskén) is a beta-adrenoceptor blocking agent with intrinsic sympathomimetic effect and is characterized by high potency and long duration.